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ABSTRACT
Lip cancer is one of the most prevalent skin tumours of the head and neck. The characteristics of the tumour relate to 
their exophyitic growth in an area of easy visual acces which allows their diagnosis in early stages. As a result, there is 
a better prognosis with the present treatments. In early stages the treatment can be performed by surgery or by brachy-
therapy, and the results are similar on local control; nevertheless brachytherapy offers the best functional and esthetic 
results. We are reporting on a review of the literature in relation to indications, techniques and results of brachytherapy 
for lip cancer.
Key words: Lip cancer, radiotherapy, interstitial brachytherapy.
RESUMEN
El cáncer de labio es de los más prevalentes entre los tumores cutáneos de cabeza y cuello. Las características del tumor, 
por su crecimiento exofítico en una zona de fácil acceso visual, permite un diagnóstico en estadios incipientes y, por 
tanto, un mejor pronóstico con los actuales tratamientos. En estadios iniciales se puede realizar tratamiento con cirugía 
o braquiterapia, siendo los resultados similares en cuanto al control local; sin embargo la braquiterapia ofrece mejores 
resultados estéticos y funcionales. Presentamos un trabajo de revisión bibliográfica al respecto de de las indicaciones, 
técnicas y resultados de la braquiterapia en el cáncer de labio.
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INTRODUCTION
Lip cancer is the second most common type of skin cancer 
in the head and neck area. There are 3.600 new cases per 
year recorded in USA (1,8 persons per 100.000 habitants 
per year.) ( 1). It normaly affects men over the age of 50 and 
in 95% of the cases the majority of the tumours are located 
in the lower lip. Tobacco habits, similar to what happens 
in the superior aerodigestive neoplasms, are an important 
aethiologic factor, and principally their frequency is in-
creased in pipe smokers. Exposure to the sun also increases 
the risk, and it  is probably the most important aetiologic 
factor, which is reflected by the high prevalence in farmers 
and other professionals exposed to the sun. The patients 
more genetically susceptible to developing skin cancer after 
sun exposure have also an increased risk of developing lip 
cancer (1-3). They can also be related to inmunosupression 
situations, and as a consequence there is an increased inci-
dence in patients who have had renal or hepatic transplants 
(3). The most frequent pathological type is the squamous 
carcinoma and with much lower frequency is the basal cell 
carcinoma type, and other pathologies are exceptional (1-3). 
In the majority of cases the clinical manifestation is as an 
exophytic or scab lesion in the lower lip, and ocassionally it 
can also bleed and be painful. Its growth is normally slow 
and, due to that there are visible lesions, their diagnosis 
is done when they are small tumours. When diagnosed, 
90% are located in the lower lip,they are well differentiated 
and their size should be aproximately 1 cm; 5% affect the 
upper lip and 1-2% affect commissure and the adjacent lip 
(3). As their growth and progression is local, in advanced 
tumours their largeness cause the invasión of the neigh-
borhood structures, as the trigeminal nerve, destruction of 
the mandibular bone or inferior alveolar orifice, and the 
infiltration of the cheek and floor of the mouth. Also as a 
consequence, patients can have alterations in the sensitivity 
of the face or pain, and are possible relevant esthetic defects 
caused by the tumour destruction of the adjacent tissues (2). 
Lymphatic spreading is infrequent and only 5-10% develop 
node metastasis at diagnosis. In lower lip tumours the more 
frequently affected lymph nodes are the submandibular 
and submental and after these the following node level is 
the upper jugular one.  Moreover, the bilateral lymph node 
dissemination can appear in lip cancer. In tumours affecting 
the upper lip and the commissure, the lymphatic spread can 
be more extensive and can disseminate to preauriculars, 
infraparotíds, buccinator of homolateral cheek and sub-
mandibulars nodes; and from there to the upper yugular 
ones. The incidence of node metastasis principally depends 
on the pathological degree and the stage, and they are more 
frequent in advanced stages and in undifferentiated cases 
(2,3). At diagnosis those tumours well differentiated present 
7% of node metastasis, moderately differentiated make up 
23% and those undifferentiated represent 35%; depending 
on the tumor size the node metastasis appear in 5% of T1, 
in 52% of T2 and can reach up to 73% in T3. Distant me-
tastasis in lip cancer are very rare and they appear in those 
cases of extensive tumors without local control. In table 1 
TMN classification of lip cancer is reflected (4).
The prognosis of these tumours principally depend on the 
size of  the tumor size; T1 tumours have 5 year survival 
rates of 90%-95%, T2 cases of 75%-85%, while in T3-T4 
there is a more drastic decrease in survival depending on 
the existence of node involvement. In stages I & II the local 
control at 5 years is 94%, in stage III it is 90% and for stage 
IV it is 47% (5). Other influencing factors on prognosis 
are the node metastasis when present there is a decrease in 
survival of 50%, the presence of vascular and lymphatic 
space invasion and the perineural invasion; age has also been 
considered as having an influence on prognosis, where the 
younger patients have a worse outcome related to a more 
aggresive disease (6).
TREATMENT OF LIP CANCER
In early stages surgery and radiotherapy are the elective 
treatment. Surgery allows to maintain the lip struture in 
displasias and in situ carcinoma;  when these lesions affect 
less than 30% of the lip they can be  treated by a V excision 
and primary closure (2,3,5). T1-T3 squamous carcinomas 
can be treated by surgery or radiotherapy. The choice of 
which treatment depends on the size of the tumour, the 
location in the lip and the expected functional and esthetic 
results with each therapeutic option. In the smaller lesions 
with easy excision, surgery can be the elective treatment if  
the size of the open mouth has not visibly reduced, although 
brachytherapy offers the same results in local control and 
survival; nevertheless, in lesions near to commisure brachy-
therapy is indicated to better preserve the esthetic results 
and lip function. In advanced stages (III-IV), surgery can be 
the treatment of choice that is frequently in need of plastic 
reconstruction, and in these cases radiotherapy is admin-
istered postoperatively. T3-T4 N0 tumours and in those 
with clinical node involvement a neck lymphadenectomy is 
recomended; when the pathologic study show node metasta-
sis radiotherapy should be administered on the tumor and 
on the lymph node areas. In very advanced tumours where 
surgery is not possible, external beam irradiation alone or 
associated with chemotherapy is the unique therapeutic 
option; in these patients, brachytherapy administered after 
external beam irradiation (EBI) allows an increased dose 
in a smaller volume. Patients with T1-T3 tumours, micro-
scopic residual disease after surgery and those cases having 
perineural involment should receive EBI or brachytherapy 
depending on the characteristics of each case. When the 
tumour involves the bone, local control and survival are 
poor despite the treatment. In those cases treated for local 
relapse where surgery or radiotherapy is performed with a 
curative aim, the local control is obtained in 50% and the 
specific overall survival at 5 years is of 30%; in this situa-
tion surgery is chosen when the patient has been previously 
irradiated, and radiotherapy is ussually administered when 
surgery is not possible due to the size of the tumour or a 
loss of lip function. (2,3,5,7,8).
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BRACHYTHERAPY
Brachytherapy is a kind of radiotherapy where radioactive 
sources are placed inside or in contact with the tumour or in-
side natural cavities. In the case of lip cancer the radioactive 
sources are introduced inside the tumour using specifically 
designed applicators that will be described further on, and 
usually are comfortable and unpainful for the patient. 
The most usual radiactive source is low dose rate (LDR) 
192Ir, and recently, treatments with high dose rate (HDR) 192Ir 
sources have been introduced. These radioactive materials 
are miniaturized and allowed to administer a high tumour 
dose. Brachytherapy is considered by their defenders as 
the best conformation possible in lip cancer treatment; 
the irradiated volume is small and adapted to the tumour 
requirements; by the treatment of the tumour with a small 
Tx Primary Tumour cannot be assessed 
T0  No evidence of primary tumour. 
Tis Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension. 
T2 Tumour more than a 2 cm but not more than 4 cm in greatest dimension. 
T3 Tumour more than 4 cm in greatest dimensión. 
T4 
Direct extension to other structures. 
T4a: Tumour invades through cortical bone, inferior alveolar nerve, floor of 
the mouth or skin (chin or nose). 
T4b: Tumour invades masticator space, pterigoid plates, or skull base, or 
encases internal carotid artery.  
 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastases. 




Metastasis in a single ipsilateral lymph node, more than 3 cm but not more 
than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none 
more than 6 cm in greatest dimension; or in bilateral or contralateral lymph 
nodes, none more than 6 cm in greatest dimension. 
N2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension. 
N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension.  
N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm 
in greatest dimension.  
 
N3 Metastasis in a lymph node more than 6 cm in greatest dimension. 
MX Distant metastasis cannot be assessed. 
M0 No distant metastasis. 
M1 Distant metastasis. Table 1.  TMN clinical classification 
for lip cancer.
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safety margin brachytherapy offers a smaller treament vo-
lume in comparison to external beam irradiation. Another 
advantage is while the dose inside the tumour is high a quick 
decrease exists in the periphery of the implant avoiding the 
irradiation of healthy neighbouring tissues. This kind of 
treatment has been performed for approximately 100 years 
and the main advantage it offers is that it maintains the 
esthetics and function of the lip. (Fig. 1)  (8). 
1- INDICATIONS.
Brachytherapy alone or combined with external beam 
irradiation, offers the same results in local control and sur-
vival than surgery. Different authors refer to the  esthetic 
and funtional benefits of brachytherapy in comparison to 
surgery. That is the reason why in some European hospitals 
brachytherapy is the treatment of choice in lip cancer. The 
majority of lip cancer cases are diagnosed in early stages, 
and while surgery ensures good functional and esthetic 
results in superficial tumours and in those having less than 
0,5 cm, brachytherapy as an exclusive treatment is indica-
ted in  practically 90% of T1-T2 lip cancer (8). In a study 
performed in 1993 by the GEC-ESTRO Society (Groupe 
Européen de Curietherapie, of the European Society for 
Therapeutic Radiology and Oncology), in 1870 patients 
treated by brachytherapy the results were 98,4% local control 
at 5 years of  98,4% for T1, 96,6% for T2 and 89,9% for T3 
(10). The results of local control, esthetics and complica-
tions for brachytherapy in lip cancer in different studies are 
shown in table 2. 
The treatment recommended for the tumours with a size 
bigger than 5 cm. is external beam irradiation followed by 
brachytherapy as a boost. Brachytherapy is contraindicated 
in those cases with bone involvement, and in those cases with 
an important loss of tissues; in these cases a wide excision 
with plastic reconstruction is of preference (2,3,5,8,9). 
2-TÉCHNIQUE.
The placement of vectors or applicators for 192Ir sources on 
the lip is usually performed using local anesthetic on the 
upper and lower alveololabial groove and only ocassionally 
it is necessary to use local anesthesia of the infraorbitary 
nerve; in some cases a general anesthesia is essential for the 
placement of the applicators (10).
There are different types of applicators and the technique 
of their placement can vary in the function of each one. 
Hypodermic needles, guide needles, plastic tubes, silk 
threads, small vascular catheters and guide gutters have 
been used along the years. The use of one vector or ano-
ther depends on the size of the tumor, their morphological 
characteristics, the lip anatomy and of the extension to the 
commissure. The plastic tube technique is recommended 
in those cases where the tumour affects the commisure or 
the cheek, and in those cases where the size of the tumour 
causes an anatomical distortion; moreover it is a comforta-
ble technique for the tumours of the upper lip. The rigid or 
guide needles technique offers better geometric conditions 
for the implant, it is the most commonly used technique for 
lower lip cancer and, this technique is highly recommended 
for HDR treatments (3,8,11).
As a main characteristic, the implant should have a geometry 
in paralelism and homogeneous distance between the radio-
active sources, and independently of the treatment technique. 
The Paris System rules recommend distances between the 
sources of 9 to 12 mm; this last point allows an optimized im-
plant avoiding overdosing areas responsible for complications 
and infradosing areas that condition relapses (8,11-13). 
The 192Ir applicators can cause lip oedema after their placement, 
principally in big tumours or in lips with lax tissue; sometimes, 
slight pain can also appear but it disappears using minor anal-
gesics. If lip oedema causes an increase of the distance between 
the sources the result is infradosing areas in the tumour; in this 
situation the administration of corticoids are useful. Usually 
the applicators are very well tolerated by the patient during the 
3-5 days that the treatment takes (8,10). 
The lip implant is frequently in contact with the opposite 
healthy lip and also with the teeth; sometimes it can be in 
contact with the maxillar bone and it principally happens 
in patients without teeths or in tumours that exceed the 
inferiority of  the vermillon. To avoid the irradiation of 
these healthy tissues they should be constructed personal-
ized protectors of acrilic material containing 2 mm of lead, 
which avoid the irradiation of neighborhood tissues of a 
factor of 2, and as a result of their use the sequelae in the 
healthy tissues should be practically non existent. Prior to 
the placement of the implant, it is necessary to check the 
adaptation and the comfort of the protector, preferably by 
a dentist, to avoid the risk of patient intolerance during 
the treatment. Throughout the treatment it is necessary to 
be vigilant with the correct position of the protector and 
to maintain the correct geometry of the implant. Before 
the brachytherapy it is strongly advisable that the patient 
is evaluated by a dentist to eliminate or restore the teeth 
in order to avoid infection during brachytherapy or in the 
Fig. 1. 1a y 1b: T1 squamous carcinoma, manifesting an ulcerous and 
costrous tumour affecting an external third of the inferior lip. 1c: Brach-
yterapy using Delclos rigid needles technique for LDR 192Ir sources. 1d: 
Disparition of the tumour 2 months after brachytherapy with excellent 
esthetic and funtional results.
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future; it is also advisable to give instructions relating to 
measures of oral hygeine (8,10,11). 
The length of the treated lip is variable in the function of the 
size of the tumour.  Normally, the length of the implanted area 
is those of the tumour plus a margin of security of 0,5-1 cm. It 
shoul be taken into account that these treatments need special 
care with the implant technique, determination of the number 
of the sources and the active 192Iridium lenght that would be 
introduced inside the vectors in order to avoid relapses in the 
edge of the treated area; because of that some authors recom-
mend the treatment of the whole length of the lip (8,11-13).
Once vectors are introduced in the lip, a personalized dosi-
metric study is necessary. This is computerised and a Com-
putarised Tomography (CT) can be necessary depending on 
the cases in order to correctly evaluate the dose distribution 
in the healthy tissues and in the tumour. Brachytherapy in 
lip cancer is in need of performing the orthogonal X-rays 
or CT for the dosimetric study using a copy of the acrilic 
protector without lead in the patients mouth; this allows 
the reproduction of the geometry implant in the dosimetric 
study as it would be during the treatment (8,10,11,13-15).
During the whole of  the treatment using low dose rate 
(LDR) 192Ir, the patient is isolated in a radiation protected 
room that should have external television monitors in order 
for nurses to exercise patient control. Once the treatment 
is finished the 192Ir and vectors are taken out of the patient 
without problems. In those cases where pain was expected 
during the removal of the implant the administration of an 
analgesic and a sedative is useful (8,10).
  
The patients that can not tolerate the isolation are special 
candidates for HDR 192Ir treatments. In this therapy several 
treatment fractions are administered during a few minutes 
a day, usually during a week.
3- COMPLICATIONS AND ESTHETIC  RESULTS.
During the first 3 weeks after treatment a proggressive 
mucositis appears in the treated area, it usually disappears 
in 1-1,5 months and rarely lasts longer than 2 months. The 
treatment is based on topic measures and anagesics / anti-
inflamatories of variable potency depending on the needs of 
the patient. Lip cancer disappears during the first 2 months 
after brachytherapy (Fig. 1d) (8,10).
The dose of brachytherapy depends on the size and charac-
teristics of the tumour. For T1 tumours doses of 60-65 Gy 
in the 85% isodosis are considered adequate and 65-70 Gy 
for T2. Advanced tumours, when tumour characteristitcs 
permit it, are treated by external beam irradiation followed 
by a brachytherapy boost; after a dose of 45-50 Gy by ex-
ternal beam irradiation a brachytherapy dose of 20-25 Gy is 
recommended. Total dose after combined treatment higher 
than  70-75 Gy can be related to an unacceptable risk of se-
quelae. Although there is no clear influence of the dose rate 
in local control, 45-90 cGy / hour are considered the most 
adequate; nevertheless, more than 6% of lip ulceration are 
described when the dose rate is higher than 80 cGy / hour. 
These lip ulcerations disappear in the majority of the cases 
with topic measures (8,16,17).
The more frequent late complications, depending on the 
study, are slight depigmentation in 2,5-17%, slight tel-
AUTHOR NºCASES DOSE  (Gy) 5 YEARS 
LC 
FUNCTIONAL AND ESTHÉTICS COMPLICATIONS 
Beauvois et al. (13) 237 (T1-T4) 65- 68 99% 198 Sligth telangiectasia, 5 moderate 
retraction and depigmentation. 
11% ulceratión, 
0.5% necrosis 
Farrús et al. (12) 72 (T1-T3) 62-67 85% - - 















Fongione et al. (14) 69 (T1-T3) 65 99% - - 
Gerbaulet et al. (22) 231 (T1-T3) Mean of 76 Gy 95% Good 70%, moderate 16%, poor 4% 13% necrosis (T3) 




8-10 fx,2 fx / day , 
6 hours. interval 
87% Similar  to LDR Similar to LDR 




Normal: T1 82%, T2 51%, T3 27%. 
Acceptable:T1 17%, T2 44%, T3 64% 
Unfavorable: T1 1%, T2 5%, T3 9% 
 
- 








4 %  necrosis 
11% pigmentation 
1% localized  edema 
5% slight retraction 
Table 2. Brachytherapy results: local control, esthetics and complications. 
LC: Local Control. HDR: High dose rate. Fx: fraction.
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angiectasias in 15% and different degrees of fibrosis in 8%. 
These are evaluated for the esthetic results and their low 
relevance means that they are well accepted by the patient. 
The most relevant late complication is the superficial necro-
sis that provokes lip ulceration; it appears in less than 10% 
of the cases, their health is usually spontaneous and in only 
5% of them a surgical treatment is required depending on 
the series. The incidence of lip ulceration is related to the 
total dose and the rate of the dose and their apparition is 
rare if  the geometry of the implant and the total dose and 
the dose rate have not been high. In brachytherapy with 
LDR sources esthetic results are related to the total dose 
and dose rate; they are considered as good or excellent in 
91% of cases when the total dose is lower than 70 Gy and 
they are described as poor in 8,6% of the cases when the 
dose rate is higher than 80 cGy / hour (1,8,11). Beauvois 
et al. (13) also report that late complications are related to 
the healthy tissues included in the 85% isodosis. Fongione 
et al. (14), showed poor esthetic results when multiplanar 
implants were used. The results of both authors make rel-
evance to the fact that the bigger the tumour, the higher the 
number of  192Ir sources and as a consequence the implant 
volume, the healthy tissue included in it and probably the 
total dose is higher; the worse esthetic results are a conse-
quence of these factors. A study performed in our hospital 
in patients treated by T1-T2 tongue carcinoma found that 
complications were increased in those patients with the high-
est treament volume.  (18). This increase in complications 
in patients that required a higher treatment volume is also 
reported in other tumour sites.
The GEC-ESTRO study, on 2794 patients, showed the fol-
lowing esthetic results:  excellent in 94,9% of T1, in 84,3% 
of T2, in 72,5% of T3 and in 60% of T4; results were poor 
in 1,4% of T1, in 4,1% of T2, in 10,1% of T3 and in 20% 
of T4. Deformity and retraction of the lip was present in 
6% of the patients with the tumour affecting commissure 
and it was more frequent in those cases of large tumours 
extended to the commissure (6).
Mazeron et al. (19) described, in 1870 patients with lip 
cancer treated by brachytherapy, the presence of relevant 
functional and esthetic sequelae in 1% of T1, in 5% of T2 
and in 9% of T3. 
There is not much experience in the treatment of lip cancer 
using HDR sources, and the lack of wide series makes it dif-
ficult to establish definitive conclusions in different aspects 
related to the total dose, optimal number of fractions and 
dose per fraction. Moreover, the lack of long follow-up in 
the series makes it difficult to define the effectiveness in 
local control, survival and esthetic and functional results. 
The largest series published in the literature and with the 
longest follow-up is by Guinot et al. (20); These authors 
studied 39 patients having a mean follow-up of 18 months 
(range between 1 and 36 months), and they reported a local 
control of 100% (21/39) in  T1, 83% (6/39) in T2 and 75% 
(12/39) in T4, with an overall survival in this series of 91%. 
Treatment was administered twice a day, 6 hours between 
fractions, the total dose ranged between 40.5 Gy and 45 Gy 
in 8 to 10 fractions and the dose per fraction was between 5 
Gy and 5.5 Gy in the majority of the cases. The authors also 
report that the seriousness and the time that mucositis need 
to health was the same as in LDR treatments. Functional re-
sults were maintained in all the patients and as late sequelae 
indicate slight pain and diffuse atrophy. Although these pre-
liminary results are encouraging in obtaining local control, 
avoiding patient isolation and permiting radioprotection of 
the staff, in HDR treatments special attention should be 
paid to the treatment technique. The rigid vectors with an 
external fixed system to ensure a good implant geometry 
are mandatory. Finestres, in 2003 (21), reported the results 
of a study, in 49 patients with T1 tumours and 7 with T2 
tumours using 192Ir HDR sources;  in these patienes a total 
dose of 60-70 Gy was administered by personalized mould 
technique, 1,8 Gy / day, 5 days / week. Disease free-survival 
at 5 years was 96,5%, esthetic results were considered as 
good or excellent in 53/56 (94.6%) and the mean follw-up 
of the patients was 46 months (range between 13 and 106 
months). The dose per day used in this study is similar to the 
external beam treatments and as a consequence the patients 
finish the treatment in a period of nearly two months. The 
advantages of HDR treatments in lip cancer mean that the 
patient does not need to be isolated, the staff  do not need 
radioprotection measures and it costs less in comparison 
to LDR treatments.
Brachytherapy is an excellent treatment in lip cancer, prin-
cipally in the early stages, where it can offer similar results 
to surgery in local control and survival. Its requires a care-
ful treatment technique and treatment planning. Relevant 
related complications are scarce and offer a good lip func-
tion maintaining the size of the mouth opening. The most 
frequent late effects are slight atrophy, telangiectasias and 
acromy. Trained staff, a careful patient evaluation and a 
good implant geometry will minimize these problems, and 
as a consequence the esthetic results are frequently superior 
to those obtained by surgery. 
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